{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:06:09Z","timestamp":1747973169699,"version":"3.41.0"},"reference-count":20,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Patiens with psoriasis and mild to moderate skin disease can be treated with topical agents. This review finds that the most effective topical treatment is calcipotriol and betamethasone combination formulations. Pure topical corticosteroids continue to have a role in the treatment of psoriasis, as they are available in many strengths and formulations that facilitate ease of use. In addition, the price is often lower than for the combination formulations. Topical calcineurin inhibitors can treat facial and intertriginous psoriasis to reduce the risk of skin atrophy.<\/jats:p>","DOI":"10.61409\/v06240428","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T13:24:17Z","timestamp":1731331457000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["New and old topical treatments for psoriasis"],"prefix":"10.61409","author":[{"given":"Kristian","family":"Kofoed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Fargnoli MC, De Simone C, Gisondi P et al P. Topical treatment for the management of mild-to-moderate psoriasis: a critical appraisal of the current literature. Dermatol Ther (Heidelb). 2023;13(11):2527-2547. https:\/\/doi.org\/10.1007\/s13555-023-01024-9","DOI":"10.1007\/s13555-023-01024-9"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chandy RJ, Dao DPD, Rivis CC et al. Noncorticosteroid topical therapies for the treatment of plaque psoriasis: a narrative review. J Pharm Technol. 2023;39(5):247-255. https:\/\/doi.org\/10.1177\/87551225231193057","DOI":"10.1177\/87551225231193057"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Da Silva N, Augustin M, Langenbruch A et al. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. Eur J Dermatol. 2020;1;30(3):267-278. https:\/\/doi.org\/10.1684\/ejd.2020.3768","DOI":"10.1684\/ejd.2020.3768"},{"key":"ref3","unstructured":"Bjornberg A, Hellgren L. Topical treatment with fluocinolone acetonide. 1. A double-blind investigation of the effect in eczema. 2. Preliminary observations in psoriasis. Acta Derm Venereol. 1962;42:426-32."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Levin E, Gupta R, Butler D et al. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014;25(6):501-6. https:\/\/doi.org\/10.3109\/09546634.2013.844314","DOI":"10.3109\/09546634.2013.844314"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Strober B, Kotowsky N, Medeiros R et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541. https:\/\/doi.org\/10.1007\/s13555-021-00493-0. Epub 2021 Feb 27","DOI":"10.1007\/s13555-021-00493-0"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Amiri D, Schwarz CW, Gether L, Skov L. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2023;14;103:adv00890. https:\/\/doi.org\/10.2340\/actadv.v103.6525","DOI":"10.2340\/actadv.v103.6525"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol. 1998;138(2):293-6. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02077.x","DOI":"10.1046\/j.1365-2133.1998.02077.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27-33. https:\/\/doi.org\/10.1016\/j.jaad.2008.03.045. Epub 2008 May 7","DOI":"10.1016\/j.jaad.2008.03.045"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hoelker S, Ninosu N, Buettner S et al. Patient preferences for topical psoriasis treatments: a discrete choice experiment. J Dermatolog Treat. 2022;33(5):2595-2604. https:\/\/doi.org\/10.1080\/09546634.2022.2059052. Epub 2022 Apr 4","DOI":"10.1080\/09546634.2022.2059052"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Iversen L, Lange MM, Bissonette R et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. J Eur Acad Dermatol Venereol. 2017;31(7):1188-1195. https:\/\/doi.org\/10.1111\/jdv.14250. Epub 2017 Apr 19","DOI":"10.1111\/jdv.14250"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Paul C, Stein Gold L, Cambazard F et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126. https:\/\/doi.org\/10.1111\/jdv.13859. Epub 2016 Aug 17","DOI":"10.1111\/jdv.13859"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Koo J, Tyring S, Werschler WP et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-7. https:\/\/doi.org\/10.3109\/09546634.2015.1083935","DOI":"10.3109\/09546634.2015.1083935"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Stein Gold L, Green LJ, Dhawan S et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420-425. https:\/\/doi.org\/10.36849\/JDD.2021.5653","DOI":"10.36849\/JDD.5653"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Papp KA, Thoning H, Gerdes S et al. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. J Dermatolog Treat. 2022;33(7):3005-3013. https:\/\/doi.org\/10.1080\/09546634.2022.2095330","DOI":"10.1080\/09546634.2022.2095330"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Lind M, Nielsen KT, Schefe LH et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-25. https:\/\/doi.org\/10.1007\/s13555-016-0125-6. Epub 2016 Jun 29","DOI":"10.1007\/s13555-016-0125-6"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol\/betamethasone dipropionate two-compound product (Dovobet\/Daivobet\/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155-60. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07236.x","DOI":"10.1111\/j.1365-2133.2006.07236.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lebwohl M, Kircik L, Lacour JP et al. Twice-weekly topical calcipotriene\/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269-1277. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.037. Epub 2020 Sep 18","DOI":"10.1016\/j.jaad.2020.09.037"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. JAMA Dermatol. 2021;1;157(7):788-795. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1090","DOI":"10.1001\/jamadermatol.2021.1090"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. Dermatol Ther (Heidelb). 2020;10(6):1215-1228. https:\/\/doi.org\/10.1007\/s13555-020-00457-w","DOI":"10.1007\/s13555-020-00457-w"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:25:16Z","timestamp":1747898716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V06240428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.61409\/v06240428","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}